NUC 3373

Drug Profile

NUC 3373

Alternative Names: 5-Fluorouracil ProTide - NuCana; NUC-3373

Latest Information Update: 09 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cardiff University
  • Developer NuCana
  • Class Antineoplastics; Pyrimidine nucleotides
  • Mechanism of Action DNA methylation inhibitors; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer; Colorectal cancer; Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 22 Jul 2016 Phase-I clinical trials in Breast cancer and Colorectal cancer (unspecified route) (NuCana pipeline, July 2016)
  • 16 Apr 2016 Pharmacokinetic and pharmacodynamic data from a preclinical study in cancer released presented at the 107th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top